Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.
Amifostine is an organic thiophosphate prodrug used for cytoprotection against toxic effects of radiotherapy and chemotherapy. In a European prospective study of SJS/TEN, six patients were suspected to have SJS/TEN associated with amifostine. Our findings suggest that the risk of life-threatening cutaneous adverse reactions to amifostine could be significantly increased.
Valeyrie-Allanore
Laurence
L
Department of Dermatology, Université Paris XII, Créteil Cedex, France. laurence.allanore@hmn.aphp.fr
Poulalhon
Nicolas
N
Fagot
Jean-Paul
JP
Sekula
Peggy
P
Davidovici
Batya
B
Sidoroff
Alexis
A
Mockenhaupt
Maja
M
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D004999:Amifostine / Q000009:adverse effects*; D005060:Europe; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011837:Radiation-Protective Agents / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000209:etiology*
D011837:Radiation-Protective Agents; D004999:Amifostine